GLP1R and Insulin resistance: There was compelling evidence that thiazolidinediones (TZDs) and glucagon-like peptide-1 receptor agonists (GLP-1Ras) were beneficial in treating MAFLD because they improved insulin resistance, control lipid metabolism, and dramatically lower body weight [49,50,51].